NB-PP_1170x120

generic drug

For Rxs and OTCs, Americans favor generics

For Rxs and OTCs, Americans favor generics

NEW YORK — When given a choice in purchasing a prescription or over-the-counter drug, most U.S. consumers will opt for a generic product, a new Harris Poll finds. Harris said Wednesday that of the 2,255 U.S. adults it surveyed, 69% said they would pick the generic drug more often, and 30% indicated that they would

Amneal earns ‘Company of the Year’ honors

Amneal earns ‘Company of the Year’ honors

BRIDGEWATER, N.J. — Amneal Pharmaceuticals won the award for “Company of the Year, Americas” at the 2015 Global Generics and Biosimilars Awards held in Madrid, Spain. Amneal said late Thursday that it was the second straight year the company was recognized by Generics Bulletin, a global newsletter for the generic drug and biosimilars industries. In

Lannett to buy Kremers Urban for $1.23 billion

Lannett to buy Kremers Urban for $1.23 billion

PHILADELPHIA — Lannett Co. plans to acquire Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic drug subsidiary of UCB S.A., in a $1.23 billion deal. Lannett said late Wednesday that the acquisition will add a diversified commercial product portfolio of 18 products. Kremers Urban currently markets generic products that treat a range of conditions, including

Teva to buy Allergan Generics for $40.5 billion

Teva to buy Allergan Generics for $40.5 billion

JERUSALEM — Teva Pharmaceutical Industries Ltd. plans to buy Allergan’s generic drug business for about $40.5 billion and, with the deal, has withdrawn its proposal to acquire Mylan N.V. for approximately $40 billion. Teva said Monday that Dublin, Ireland-based Allergan will receive $33.75 billion in cash and $6.75 billion in shares of Teva. The agreement